DUBLIN--(BUSINESS WIRE)--
Research and Markets (http://www.researchandmarkets.com/research/qssnjh/vx765_epilepsy) has announced the addition of GlobalData's new report "VX-765 (Epilepsy) - Forecast and Market Analysis to 2022" market research report to their offering.
PharmaPoint Drug Evaluation report, VX-765 (Epilepsy) - Forecast and Market Analysis to 2022. Epilepsy is a brain disorder characterized by spontaneously occurring and recurrent seizures. The market is heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure reduction. The AED market is currently dominated by UCB's Keppra and GlaxoSmithKline's Lamictal. Although both drugs have experienced significant generic erosion, they form the mainstay of epilepsy treatment in the nine markets and will continue to have significant market share during the forecast period. Other key drugs include older generation AEDs such as Pfizer's Dilantin, Abbott's Depakote, and Novartis' Tegretol and Trileptal which still have significant usage due to their longevity in the market. However, the AED dominance landscape will continue to shift towards newer generation drugs particularly following the recent market entry of GlaxoSmithKline's Trobalt/Potiga and Eisai's Fycompa which both offer first-in-class mechanisms of action.
VX-765 is a first-in-class CASP1 inhibitor being developed by Vertex for the treatment of epilepsy. It represents a novel approach of using anti-inflammatory compounds for the treatment of epilepsy, particularly drug-resistant cases. VX-765 has shown activity in preclinical models of chronic epilepsy that do not respond to standard AEDs. The results of a Phase II study of VX-765 in 60 people with treatment-resistant partial-onset epilepsy showed that the drug was safe and well tolerated. Based on these results, a Phase IIb study of VX-765 in people with treatment-resistant epilepsy is being conducted.
Key Topics Covered:
1 Tables & Figures
2 Introduction
3 Disease Overview
4 Disease Management
5 Competitive Assessment
Excerpt from:
Research and Markets: PharmaPoint Drug Evaluation Report - VX-765 ( Epilepsy ) - Forecast and Market Analysis to 2022